EGFR and pancreatic neoplasm: Collectively, the in vitro and in vivo findings strongly demonstrate that monensin exerts a potent inhibitory effect on cell proliferation and tumor growth in drug-resistant pancreatic cancer cells, possibly through targeting the EGFR signaling pathway.